- Home
- LUCK vs TVTX Comparison
LUCK vs TVTX Comparison
Compare LUCK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCK
- TVTX
- Stock Information
- Founded
- LUCK 1997
- TVTX 2008
- Country
- LUCK United States
- TVTX United States
- Employees
- LUCK N/A
- TVTX N/A
- Industry
- LUCK
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- LUCK
- TVTX Health Care
- Exchange
- LUCK NYSE
- TVTX Nasdaq
- Market Cap
- LUCK 1.5B
- TVTX 1.5B
- IPO Year
- LUCK N/A
- TVTX N/A
- Fundamental
- Price
- LUCK $10.02
- TVTX $20.31
- Analyst Decision
- LUCK Hold
- TVTX Buy
- Analyst Count
- LUCK 1
- TVTX 12
- Target Price
- LUCK $12.00
- TVTX $24.58
- AVG Volume (30 Days)
- LUCK 541.1K
- TVTX 1.1M
- Earning Date
- LUCK 02-05-2025
- TVTX 02-13-2025
- Dividend Yield
- LUCK 2.14%
- TVTX N/A
- EPS Growth
- LUCK N/A
- TVTX N/A
- EPS
- LUCK N/A
- TVTX N/A
- Revenue
- LUCK $1,187,404,000.00
- TVTX $203,447,000.00
- Revenue This Year
- LUCK $10.51
- TVTX $62.37
- Revenue Next Year
- LUCK $6.90
- TVTX $61.74
- P/E Ratio
- LUCK N/A
- TVTX N/A
- Revenue Growth
- LUCK 12.45
- TVTX 57.08
- 52 Week Low
- LUCK $9.61
- TVTX $5.12
- 52 Week High
- LUCK $15.47
- TVTX $21.56
- Technical
- Relative Strength Index (RSI)
- LUCK N/A
- TVTX 62.15
- Support Level
- LUCK N/A
- TVTX $16.80
- Resistance Level
- LUCK N/A
- TVTX $19.76
- Average True Range (ATR)
- LUCK 0.00
- TVTX 1.07
- MACD
- LUCK 0.00
- TVTX 0.25
- Stochastic Oscillator
- LUCK 0.00
- TVTX 73.74
About LUCK LUCKY STRIKE ENTERTAINMENT CORPORAT
Lucky Strike Entertainment Corp is a entertainment platforms. It has nearly 360 locations across North America, that provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the league of bowling and a growing media property.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.